Urothelial Carcinoma Market on Track for Major Expansion by 2036, According to DelveInsight | Bristol-Myers Squibb, Astellas Pharma, Pfizer, Johnson & Johnson, Pfizer, Tyra Biosciences, Infinity

The Key Urothelial Carcinoma Companies in the market include - Bristol-Myers Squibb, Astellas Pharma, Pfizer, Johnson & Johnson, Pfizer, Tyra Biosciences, Merck, Bicycle Therapeutics, Infinity, QED Therapeutics, BeiGene, Eli Lilly, Roche, UroGen, Nektar Therapeutics, BMS, Incyte, Abbisko, Mamta Parikh, AstraZeneca, Janssen Research & Development, LLC, Pfizer, Inovio Pharmaceuticals, Hoffmann-La Roche, RemeGen Co., Ltd., and others.

DelveInsight's "Urothelial Carcinoma Market Insights, Epidemiology, and Market Forecast-2036 report offers an in-depth understanding of the Urothelial Carcinoma, historical and forecasted epidemiology as well as the Urothelial Carcinoma market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

Get a Free sample for the Urothelial Carcinoma Market Report:

https://www.delveinsight.com/report-store/urothelial-carcinoma-market [https://www.delveinsight.com/report-store/urothelial-carcinoma-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Some of the key facts of the Urothelial Carcinoma Market Report:

*
The Urothelial Carcinoma market size is anticipated to grow with a significant CAGR during the study period (2022-2036).

*
In April 2026, Mabwell announced that it will showcase the latest clinical findings on 9MW2821 in combination with toripalimab for the treatment of urothelial carcinoma through both oral and poster presentations at ASCO 2026, highlighting recent progress and emerging efficacy data from the ongoing development program.

*
In February 2026, Emerging NMIBC Therapies Featured at ASCO GU: Several investigational treatment programs for non-muscle-invasive bladder cancer (NMIBC), including recombinant BCG (rBCG)-based candidates and advanced immunotherapy approaches, were showcased at the ASCO Genitourinary Cancers Symposium. These development efforts are focused on overcoming persistent BCG supply challenges while enhancing long-term disease management and patient outcomes.

*
In January 2026, Final Results from the Phase II NORSE Trial: The Phase II NORSE study demonstrated promising clinical activity with erdafitinib both as a monotherapy and in combination with cetrelimab as a first-line treatment for cisplatin-ineligible patients with metastatic urothelial carcinoma harboring FGFR alterations. The results reinforce the potential of biomarker-guided therapeutic strategies and support further development of precision medicine approaches in advanced urothelial cancer.

*
In November 2025, Pembrolizumab + Enfortumab vedotin-ejfv, The US FDA approved pembrolizumab in combination with PADCEV as perioperative treatment for cisplatin-ineligible patients with muscle-invasive bladder cancer (MIBC), marking a major expansion of ADC + immunotherapy use in earlier-stage disease.

*
In June 2025, the data of OPDIVO + YERVOY for cisplatin-ineligible metastatic urothelial carcinoma, presented at the ASCO 2025, failed to improve the overall survival.

*
In April 2025, UroGen Pharma initiated the Phase III trial of UGN-104 for the treatment of patients with low-grade upper tract urothelial carcinoma.

*
In February 2025, Pfizer and Astellas announced updated results from the Phase III EV-302 (KEYNOTE-A39) trial, showing sustained Overall Survival (OS) and Progression-free Survival (PFS) benefits with PADCEV + KEYTRUDA in previously untreated locally advanced or metastatic urothelial carcinoma after a median follow-up of 29.1 months. Additionally, the data was also presented at ASCO GU 2025 in San Francisco, CA, on February 1

*
In February 2025, Phase I findings for SHR-A2102 in individuals with advanced or metastatic urothelial carcinoma were presented at the 2025 ASCO Genitourinary Cancers Symposium.

*
According to DelveInsight's estimates, in 2025, there were nearly 206,300 incident cases of urothelial carcinoma in the 7MM.

*
In EU4 and the UK, males accounted for more incident cases of urothelial carcinoma, i.e., nearly 75%, as compared to females, in 2025.

*
As per the analysis, the median age of diagnosis of urothelial carcinoma is 69 years in men and 71 years in women.

*
Tumors occurring in along the renal calyces and renal pelvis are twice as common as tumors found in the ureters. Carcinoma in situ (CIS) in the upper urinary tract may exist in 11-36% of individuals and UTUC can be multifocal in 10-20% of patients. Over 60% of UTUCs are muscle invasive at diagnosis and about 17% of cases are synchronous with a bladder tumor.

*
Among the mutations observed in urothelial carcinoma, approximately 50% of the patients had a TP53 mutation, followed by a FGFR3 mutation (nearly 30%) in the United States.

*
Following treatment for UTUC, recurrence in the bladder occurs in 29% of UTUC patients, depending on patient-, tumour- and treatment-specific characteristics compared to a 2-5% recurrence rate in the contralateral upper tract.

*
Nearly all cases of urothelial carcinoma are UBCs, whereas UTUC accounts for just 5-10% of all urothelial malignancies.

*
In the United States in 2025, Urothelial Carcinoma was found to be more incident in age group 80 years and above (~30,000) followed by age group 70-79 years.

*
In Japan, among stage specific urothelial carcinoma in 2025, Non-muscle invasive urothelial carcinoma was found to be more incident (~15,600 cases), followed by muscle invasive urothelial carcinoma with locally advanced or metastatic urothelial carcinoma was the lowest.

*
Key Urothelial Carcinoma Companies: Bristol-Myers Squibb, Astellas Pharma, Pfizer, Johnson & Johnson, Pfizer, Tyra Biosciences, Merck, Bicycle Therapeutics, Infinity, QED Therapeutics, BeiGene, Eli Lilly, Roche, UroGen, Nektar Therapeutics, BMS, Incyte, Abbisko, Mamta Parikh, AstraZeneca, Janssen Research & Development, LLC, Pfizer, Inovio Pharmaceuticals, Hoffmann-La Roche, RemeGen Co., Ltd., and others

*
Key Urothelial Carcinoma Therapies: Nivolumab (OPDIVO), Enfortumab vedotin-ejfv (PADCEV), Erdafitinib (BALVERSA), Disitamab vedotin (AIDIXI), Dabogratinib (TYRA-300), KEYTRUDA (pembrolizumab), OPDIVO (nivolumab), BT8009, Eganelisib + Opdivo, Infigratinib, Tislelizumab, Cyramza, Tecentriq, UGN-102, Bempegaldesleukin, Pemazyre (Pemigatinib), ABSK091/AZD4547, Selinexor, Tremelimumab, Erdafitinib, Niraparib, Atezolizumab, RC48-ADC, and others

*
The Urothelial Carcinoma epidemiology based on gender analyzed that Urothelial carcinoma in males has two-to-three fold greater incidence as compared to females

*
The Urothelial Carcinoma market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Urothelial Carcinoma pipeline products will significantly revolutionize the Urothelial Carcinoma market dynamics.

Urothelial Carcinoma Overview

Urothelial Carcinoma is the most common type of bladder cancer, arising from the urothelial cells that line the urinary tract, including the bladder, ureters, and renal pelvis. It accounts for the majority of bladder cancer cases and can be classified as non-muscle-invasive or muscle-invasive depending on the depth of tumor penetration.

To Know in detail about the Urothelial Carcinoma market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Urothelial Carcinoma Market Forecast [https://www.delveinsight.com/sample-request/urothelial-carcinoma-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Urothelial Carcinoma Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2022 to 2036. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Urothelial Carcinoma Epidemiology Segmentation:

The Urothelial Carcinoma market report proffers epidemiological analysis for the study period 2022-2036 in the 7MM segmented into:

*
Total Incident Cases of Urothelial Carcinoma

*
Gender-specific Incident Cases of Urothelial Carcinoma

*
Age-specific Incident Cases of Urothelial Carcinoma

*
Mutation-specific Incident Cases of Urothelial Carcinoma

*
Stage-specific Incident Cases (localized, regional, and distant [metastatic {de novo + recurrent}]) of Urothelial Carcinoma

*
Line-wise Treated Cases of Urothelial Carcinoma

Download the report to understand which factors are driving Urothelial Carcinoma epidemiology trends @ Urothelial Carcinoma Epidemiology Forecast [https://www.delveinsight.com/sample-request/urothelial-carcinoma-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Urothelial Carcinoma Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Urothelial Carcinoma market or expected to get launched during the study period. The analysis covers Urothelial Carcinoma market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Urothelial Carcinoma Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Urothelial Carcinoma Therapies and Key Companies

*
Nivolumab (OPDIVO): Bristol-Myers Squibb

*
Enfortumab vedotin-ejfv (PADCEV): Astellas Pharma/Pfizer

*
Erdafitinib (BALVERSA): Johnson & Johnson

*
Disitamab vedotin (AIDIXI): Pfizer

*
Dabogratinib (TYRA-300): Tyra Biosciences

*
KEYTRUDA (pembrolizumab): Merck

*
OPDIVO (nivolumab): Bristol Myers Squibb

*
BT8009: Bicycle Therapeutics

*
Eganelisib + Opdivo: Infinity

*
Infigratinib: QED Therapeutics

*
Tislelizumab: BeiGene

*
Cyramza: Eli Lilly

*
Tecentriq: Roche

*
UGN-102: UroGen

*
Bempegaldesleukin: NektarTherapeutics /BMS

*
Pemazyre (Pemigatinib): Incyte

*
ABSK091/AZD4547: Abbisko

*
Selinexor: Mamta Parikh

*
Tremelimumab: AstraZeneca

*
Erdafitinib: Janssen Research & Development, LLC

*
Niraparib: Pfizer

*
Atezolizumab: Inovio Pharmaceuticals

*
Atezolizumab: Hoffmann-La Roche

*
RC48-ADC: RemeGen Co., Ltd.

Discover more about therapies set to grab major Urothelial Carcinoma market share @ Urothelial Carcinoma Treatment Market [https://www.delveinsight.com/sample-request/urothelial-carcinoma-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Urothelial Carcinoma Market Drivers

*
Rising incidence of bladder cancer and urothelial carcinoma worldwide, particularly among aging populations.

*
Increasing adoption of immunotherapies, including immune checkpoint inhibitors, for advanced and metastatic disease.

*
Expanding availability of targeted therapies and antibody-drug conjugates (ADCs) improving treatment outcomes.

*
Growing use of precision medicine, biomarker testing, and molecular profiling to guide therapy selection.

*
Strong pipeline of novel therapeutics across immuno-oncology, targeted therapy, and combination treatment approaches.

Urothelial Carcinoma Market Barriers

*
High treatment costs associated with immunotherapies, targeted agents, and combination regimens.

*
Significant disease recurrence rates requiring long-term monitoring and repeated interventions.

*
Development of treatment resistance, particularly in advanced and metastatic urothelial carcinoma.

*
Limited efficacy of existing therapies in certain patient subgroups and late-stage disease.

*
Stringent regulatory requirements and lengthy clinical development timelines for novel oncology therapies.

Scope of the Urothelial Carcinoma Market Report

*
Study Period: 2022-2036

*
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

*
Key Urothelial Carcinoma Companies: Bristol-Myers Squibb, Astellas Pharma, Pfizer, Johnson & Johnson, Pfizer, Tyra Biosciences, Merck, Bicycle Therapeutics, Infinity, QED Therapeutics, BeiGene, Eli Lilly, Roche, UroGen, NektarTherapeutics /BMS, Incyte, Abbisko, Mamta Parikh, AstraZeneca, Janssen Research & Development, LLC, Pfizer, Inovio Pharmaceuticals, Hoffmann-La Roche, RemeGen Co., Ltd., and others

*
Key Urothelial Carcinoma Therapies: Nivolumab (OPDIVO), Enfortumab vedotin-ejfv (PADCEV), Erdafitinib (BALVERSA), Disitamab vedotin (AIDIXI), Dabogratinib (TYRA-300), KEYTRUDA (pembrolizumab), OPDIVO (nivolumab), BT8009, Eganelisib + Opdivo, Infigratinib, Tislelizumab, Cyramza, Tecentriq, UGN-102, Bempegaldesleukin, Pemazyre (Pemigatinib), ABSK091/AZD4547, Selinexor, Tremelimumab, Erdafitinib, Niraparib, Atezolizumab, RC48-ADC, and others

*
Urothelial Carcinoma Therapeutic Assessment: Urothelial Carcinoma current marketed and Urothelial Carcinoma emerging therapies

*
Urothelial Carcinoma Market Dynamics: Urothelial Carcinoma market drivers and Urothelial Carcinoma market barriers

*
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies

*
Urothelial Carcinoma Unmet Needs, KOL's views, Analyst's views, Urothelial Carcinoma Market Access and Reimbursement

To know more about Urothelial Carcinoma companies working in the treatment market, visit @ Urothelial Carcinoma Clinical Trials and Therapeutic Assessment [https://www.delveinsight.com/sample-request/urothelial-carcinoma-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Table of Contents

1. Urothelial Carcinoma Market Report Introduction

2. Executive Summary for Urothelial Carcinoma

3. SWOT analysis of Urothelial Carcinoma

4. Urothelial Carcinoma Patient Share (%) Overview at a Glance

5. Urothelial Carcinoma Market Overview at a Glance

6. Urothelial Carcinoma Disease Background and Overview

7. Urothelial Carcinoma Epidemiology and Patient Population

8. Country-Specific Patient Population of Urothelial Carcinoma

9. Urothelial Carcinoma Current Treatment and Medical Practices

10. Urothelial Carcinoma Unmet Needs

11. Urothelial Carcinoma Emerging Therapies

12. Urothelial Carcinoma Market Outlook

13. Country-Wise Urothelial Carcinoma Market Analysis (2022-2036)

14. Urothelial Carcinoma Market Access and Reimbursement of Therapies

15. Urothelial Carcinoma Market Drivers

16. Urothelial Carcinoma Market Barriers

17. Urothelial Carcinoma Appendix

18. Urothelial Carcinoma Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=urothelial-carcinoma-market-on-track-for-major-expansion-by-2036-according-to-delveinsight-bristolmyers-squibb-astellas-pharma-pfizer-johnson-johnson-pfizer-tyra-biosciences-infinity]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.